Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 89.09 USD 0.99% Market Closed
Market Cap: 9.4B USD
Have any thoughts about
Intra-Cellular Therapies Inc?
Write Note

Intra-Cellular Therapies Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intra-Cellular Therapies Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Operating Income
-$121.6m
CAGR 3-Years
22%
CAGR 5-Years
5%
CAGR 10-Years
-18%
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.2B
CAGR 3-Years
-1%
CAGR 5-Years
7%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$11.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Operating Income
$13.1B
CAGR 3-Years
-17%
CAGR 5-Years
63%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Operating Income
$21.7B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
10%
Eli Lilly and Co
NYSE:LLY
Operating Income
$14.4B
CAGR 3-Years
25%
CAGR 5-Years
21%
CAGR 10-Years
15%

See Also

What is Intra-Cellular Therapies Inc's Operating Income?
Operating Income
-121.6m USD

Based on the financial report for Sep 30, 2024, Intra-Cellular Therapies Inc's Operating Income amounts to -121.6m USD.

What is Intra-Cellular Therapies Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-18%

Over the last year, the Operating Income growth was 30%. The average annual Operating Income growth rates for Intra-Cellular Therapies Inc have been 22% over the past three years , 5% over the past five years , and -18% over the past ten years .

Back to Top